PE20001587A1 - Derivados de diarilo como agentes tiromimeticos - Google Patents

Derivados de diarilo como agentes tiromimeticos

Info

Publication number
PE20001587A1
PE20001587A1 PE2000000260A PE0002602000A PE20001587A1 PE 20001587 A1 PE20001587 A1 PE 20001587A1 PE 2000000260 A PE2000000260 A PE 2000000260A PE 0002602000 A PE0002602000 A PE 0002602000A PE 20001587 A1 PE20001587 A1 PE 20001587A1
Authority
PE
Peru
Prior art keywords
alkyl
halogen
derivatives
nr5r6
alcoxyl
Prior art date
Application number
PE2000000260A
Other languages
English (en)
Inventor
Paivi Jaana Kukkola
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20001587A1 publication Critical patent/PE20001587A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/67—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfonamide groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)

Abstract

SE REFIERE DERIVADOS DE DIARILO DE FORMULA I, DONDE: W ES O, S, S(O), S(O)2; X ES SR4, S(O)R4, S(O)2R4, S(O)NR5R6, ENTRE OTROS; Y ES O, H2; Z ES H, HALOGENO, OH, ALCOXILO, ARALCOXILO, ACILOXILO, ALCOXICARBONILO; R1 ES OH, ALCOXILO, ARILOXILO, HETEROARILOXILO, ARALCOXILO, CICLOALCOXILO, HETEROARALCOXILO, NR5R6; R2 ES H, HALOGENO, ALQUILO; R3 ES HALOGENO, ALQUILO; R4 ES ALQUILO, ARILO, ARALQUILO, HETEROARALQUILO, HETEROARILO; R5, R6 Y R7 SON H, ALQUILO, CICLOALQUILO, ARILO, ARALQUILO, HETEROARILO, HETEROARALQUILO; O R5 Y R6 SON ALQUILENO OPCIONALMENTE INTERRUMPIDO CON O, S, S(O), NR7, Y CON N FORMAN UN ANILLO DE 5-7 MIEMBROS; n ES 0-4. SON COMPUESTOS PREFERIDOS ACIDO N-{4-[3-2,2-DIMETILPROPILSULFAMOIL)-4-HIDROXIFENOXI]-3,5-DIMETILFENIL}OXAMICO; ACIDO N-[4-(4-HIDROXI-3-FENILSULFAMOILFENOXI)-3,5-DIMETILFENIL]OXAMICO, ENTRE OTROS. EL COMPUESTO I ES UN AGENTE TIROMIMEMICO POR LO QUE PUEDEN SER UTILES PARA EL TRATAMIENTO DE ENFERMEDADES ASOCIADAS CON UN DESEQUILIBRIO DE LAS HORMONAS TIROIDEAS, TRATAMIENTO DE CONDICIONES CARDIOVASCULARES OCLUSIVAS, HIPO E HIPERTIROIDISMO, OBESIDAD, OSTEOPOROSIS, DEPRESION, ATEROSCLEROSIS
PE2000000260A 1999-03-29 2000-03-27 Derivados de diarilo como agentes tiromimeticos PE20001587A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28010599A 1999-03-29 1999-03-29

Publications (1)

Publication Number Publication Date
PE20001587A1 true PE20001587A1 (es) 2001-01-31

Family

ID=23071698

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000260A PE20001587A1 (es) 1999-03-29 2000-03-27 Derivados de diarilo como agentes tiromimeticos

Country Status (21)

Country Link
EP (1) EP1165502A1 (es)
JP (1) JP2002540189A (es)
KR (1) KR20010105394A (es)
CN (1) CN1345309A (es)
AU (1) AU4290800A (es)
BR (1) BR0009431A (es)
CA (1) CA2361016A1 (es)
CO (1) CO5160290A1 (es)
CZ (1) CZ20013449A3 (es)
HK (1) HK1042692A1 (es)
HU (1) HUP0200588A2 (es)
IL (1) IL144637A0 (es)
MX (1) MXPA01009843A (es)
NO (1) NO20014702D0 (es)
NZ (1) NZ514062A (es)
PE (1) PE20001587A1 (es)
PL (1) PL349355A1 (es)
RU (1) RU2001126579A (es)
SK (1) SK13812001A3 (es)
TR (1) TR200102225T2 (es)
WO (1) WO2000058279A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL144765A0 (en) 1999-03-01 2002-06-30 Pfizer Prod Inc Oxamic acids and derivatives as thyroid receptor ligands
US6790978B2 (en) 1999-03-29 2004-09-14 Novartis Ag Thyromimetic organic compounds
ES2242723T3 (es) 2000-02-17 2005-11-16 Bristol-Myers Squibb Company Ligandos derivados de anilina para el receptor de la tiroides .
CA2403902C (en) * 2000-03-31 2007-04-24 Pfizer Products Inc. Malonamic acids and derivatives thereof as thyroid receptor ligands
US6664291B2 (en) 2000-03-31 2003-12-16 Pfizer, Inc. Malonamic acids and derivatives thereof as thyroid receptor ligands
AU4884701A (en) * 2000-05-12 2001-11-20 Kissei Pharmaceutical Co. Ltd. Malonanilic acid derivatives, medicinal compositions containing the same and usethereof
US6395784B1 (en) 2000-06-07 2002-05-28 Bristol-Myers Squibb Company Benzamide ligands for the thyroid receptor
DE10038007A1 (de) 2000-08-04 2002-02-14 Bayer Ag Neue Amino-und Amido-Diphenylether für Arzneimittel
DE10046029A1 (de) 2000-09-18 2002-03-28 Bayer Ag Indazole
WO2002032408A2 (en) * 2000-10-20 2002-04-25 Novartis Ag Combinations of a thyromimetic compound and a statin
JP2004517851A (ja) * 2000-12-27 2004-06-17 バイエル アクチェンゲゼルシャフト 甲状腺受容体のリガンドとしてのインドール誘導体
US6777442B2 (en) 2001-03-12 2004-08-17 Bayer Aktiengesellschaft Diphenyl derivatives
DE10122443A1 (de) * 2001-05-09 2002-11-14 Bayer Ag Amido-Diphenyl-Derivate
US6777443B2 (en) 2001-05-15 2004-08-17 Novartis Ag Dipeptide derivatives
PT1262177E (pt) * 2001-05-31 2006-12-29 Pfizer Prod Inc Utilização medicinal de compostos tiromimético para tratamento da queda de cabelo e composições
DE10131462A1 (de) * 2001-06-29 2003-01-09 Bayer Ag Phenol-Derivate
ES2253495T3 (es) 2001-09-26 2006-06-01 Pfizer Products Inc. Acidos indol carboxilicos como ligandos de receptores tiroideos.
US6818766B2 (en) 2002-10-02 2004-11-16 Synthon Bv Process for making bicalutamide and intermediates thereof
EP2428516A1 (en) * 2003-11-19 2012-03-14 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
JP2007536348A (ja) * 2004-05-05 2007-12-13 ノボ　ノルディスク　アクティーゼルスカブ スルホンアミド誘導体
US8188277B2 (en) 2004-08-06 2012-05-29 Otsuka Pharmaceutical Co., Ltd. Aromatic compounds for suppressing the generation of collagen
CA2606499C (en) 2005-05-26 2017-06-13 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
EP1957073B1 (en) 2005-12-05 2014-04-23 Otsuka Pharmaceutical Co., Ltd. Medicinal drug
UA95978C2 (ru) 2006-10-02 2011-09-26 Оцука Фармас'Ютікел Ко., Лтд. Ингибитор активации stat3/5
WO2009133834A1 (ja) * 2008-04-28 2009-11-05 塩野義製薬株式会社 血管内皮リパーゼ阻害活性を有するケトアミド誘導体
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
CN104193699B (zh) * 2014-08-14 2016-05-25 嘉兴特科罗生物科技有限公司 一种小分子化合物及其合成方法和应用
WO2018094265A2 (en) 2016-11-21 2018-05-24 Viking Therapeutics, Inc. Method of treating glycogen storage disease
EP3634426A4 (en) 2017-06-05 2021-04-07 Viking Therapeutics, Inc. COMPOSITIONS FOR THE TREATMENT OF FIBROSIS
JP2021518403A (ja) 2018-03-22 2021-08-02 バイキング・セラピューティクス・インコーポレイテッド 化合物の結晶形態及び化合物の結晶形態を生成する方法
TW202115029A (zh) * 2019-07-31 2021-04-16 大陸商深圳微芯生物科技股份有限公司 雜環化合物及其用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE159515T1 (de) * 1992-07-21 1997-11-15 Ciba Geigy Ag Oxamidsäure-derivate als hypocholesterämische mittel

Also Published As

Publication number Publication date
HUP0200588A2 (hu) 2002-07-29
CO5160290A1 (es) 2002-05-30
BR0009431A (pt) 2002-01-08
AU4290800A (en) 2000-10-16
MXPA01009843A (es) 2002-05-06
NO20014702L (no) 2001-09-27
RU2001126579A (ru) 2004-02-27
JP2002540189A (ja) 2002-11-26
WO2000058279A1 (en) 2000-10-05
CZ20013449A3 (cs) 2001-12-12
CN1345309A (zh) 2002-04-17
TR200102225T2 (tr) 2002-01-21
SK13812001A3 (sk) 2002-04-04
IL144637A0 (en) 2002-05-23
HK1042692A1 (zh) 2002-08-23
NO20014702D0 (no) 2001-09-27
CA2361016A1 (en) 2000-10-05
EP1165502A1 (en) 2002-01-02
KR20010105394A (ko) 2001-11-28
PL349355A1 (en) 2002-07-15
NZ514062A (en) 2001-09-28

Similar Documents

Publication Publication Date Title
PE20001587A1 (es) Derivados de diarilo como agentes tiromimeticos
NO900991L (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme 2-(l-piperazinyl)-4-fenylcycloalkanopyridin-derivater
DE69310501T2 (de) Chinolylbenzofuran derivate als leukotrien-antagonisten
AR051839A1 (es) Metodo para preparar n-fenilpirazol -1- carboxamidas
DK0526434T3 (da) Benzimidazolonderivater som 5-HT1A- og 5-HT2-antagonister
PT787726E (pt) Novo composto, processo para a sua producao e agente tumoral
KR910006277A (ko) N-치환된-4-피리미딘아민 및 피리미딘디아민, 이의 제조방법 및 약제로서의 이의 용도
MY128048A (en) Phenyl- and aminophenyl- alkysulfonamide and urea derivatives.
NO933452D0 (no) Et terapeutisk middel for parkinson's sykdom
PE20050132A1 (es) Piperazinas heterociclicas sustituidas
ATE286027T1 (de) Fluorpyrazol-biphenylamide als fungizide
PE20020254A1 (es) Derivados de piridina
PE20090757A1 (es) Formulaciones que contienen triazinonas y hierro
PE98099A1 (es) Derivados de 2-(4-bromo o 4-yodo fenilamino) acido benzoico
CO5160347A1 (es) Derivados de acido carbamico
KR900007790A (ko) 항-아테롬성 동맥경화증성 디아릴 화합물
KR840006633A (ko) 벤족사졸리논 유도체의 제조방법
FR2800735B1 (fr) Nouvelles aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation
KR890011596A (ko) 불면증 치료용 의약품의 제조에 있어서 1,4-이치환-피페리디닐 화합물의 용도
KR900014388A (ko) 에세롤린의 카보네이트 유도체, 이의 제조방법 및 약제로서의 용도
AR037521A1 (es) Derivados de piperazina que tienen actividad antagonista del sst1, un proceso para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento para el tratamiento de la depresion, ansiedad y padecimientos bipolares y una combinacion
PE20040668A1 (es) Nuevos derivados de piperidina
KR920007995A (ko) 벤즈아미드 유도체
AR011521A1 (es) Un derivado de la prolil-3-(2-naftil) alanil-n-bencil-n-metilamida, un procedimiento para su preparacion y una composicion farmaceutica que lo comprende
KR910020007A (ko) 3-[1-티아졸리디닐부틸-4-피페라지닐]-1h-인다졸, 이의 제조방법 및 이의 약제로서의 용도

Legal Events

Date Code Title Description
FD Application declared void or lapsed